[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100399417":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":41,"centralContacts":48,"locations":58,"responsibleParty":86,"collaborators":10,"id":90,"slug":91,"hasResults":92,"nctId":93,"briefTitle":94,"officialTitle":94,"acronym":10,"eligibilityCriteria":95,"healthyVolunteers":92,"sex":96,"minAge":97,"maxAge":98,"enrollmentInfo":99,"targetDuration":102,"studyType":103,"phases":10,"briefSummary":104,"conditions":105,"keywords":112,"overallStatus":61,"whyStopped":10,"lastUpdateSubmitDate":115,"lastUpdatePostDateStruct":116,"startDateStruct":119,"completionDateStruct":121,"leadSponsor":123,"locationsCount":124},{"fullName":5,"class":6},"University of Iowa","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Major Depressive Episode",null,"After referral to the University of Iowa's Interventional Psychiatry Clinic, the patient will be clinically evaluated and, if appropriate, commence the procedural-based treatment course.",[13,14,15,16,17],"Device: Electroconvulsive Therapy (ECT)","Device: Transcranial Magnetic Stimulation (TMS)","Drug: Ketamine","Drug: Esketamine","Device: Deep Transcranial Magnetic Stimulation (dTMS)",[19,24,28,33,37],{"type":20,"name":21,"description":22,"armGroupLabels":23,"otherNames":10},"DEVICE","Electroconvulsive Therapy (ECT)","ECT for the treatment of treatment-resistant depression OR Bipolar Disorder in an active major depressive episode",[9],{"type":20,"name":25,"description":26,"armGroupLabels":27,"otherNames":10},"Transcranial Magnetic Stimulation (TMS)","TMS for the treatment of treatment-resistant depression in an active major depressive episode",[9],{"type":29,"name":30,"description":31,"armGroupLabels":32,"otherNames":10},"DRUG","Ketamine","Intravenous ketamine infusion for the treatment of treatment-resistant depression in an active major depressive episode",[9],{"type":29,"name":34,"description":35,"armGroupLabels":36,"otherNames":10},"Esketamine","Intranasal esketamine insufflation for the treatment of treatment-resistant depression in an active major depressive episode",[9],{"type":20,"name":38,"description":39,"armGroupLabels":40,"otherNames":10},"Deep Transcranial Magnetic Stimulation (dTMS)","TMS for the treatment of OCD",[9],[42,46],{"name":43,"affiliation":44,"role":45},"Mark J Niciu, M.D., Ph. D.","University of Iowa Hospitals & Clinics","PRINCIPAL_INVESTIGATOR",{"name":47,"affiliation":44,"role":45},"Nicholas T Trapp, M.D., M.S.",[49,54],{"name":50,"role":51,"phone":52,"phoneExt":10,"email":53},"Karin Nielsen, MS","CONTACT","319-384-6521","karin-nielsen@uiowa.edu",{"name":55,"role":51,"phone":56,"phoneExt":10,"email":57},"Emerson Buse, BA","319-353-8536","emerson-buse@uiowa.edu",[59],{"facility":60,"status":61,"city":62,"state":63,"zip":64,"country":65,"countryCode":66,"cosmosGeoPoint":67,"geoPoint":72,"contacts":73},"University of Iowa Health Care","RECRUITING","Iowa City","Iowa","52242","United States","US",{"type":68,"coordinates":69},"Point",[70,71],-91.53017,41.66113,{"lat":71,"lon":70},[74,78,82,84],{"name":75,"role":51,"phone":76,"phoneExt":10,"email":77},"Benjamin Pace, M.S.","319-384-9302","benjamin-pace@uiowa.edu",{"name":79,"role":51,"phone":80,"phoneExt":10,"email":81},"Alex Alario, B.S.","319-384-8470","alexandra-alario@uiowa.edu",{"name":83,"role":45,"phone":10,"phoneExt":10,"email":10},"Mark J Niciu, M.D. Ph.D.",{"name":85,"role":45,"phone":10,"phoneExt":10,"email":10},"Nicholas T Trapp, M.D. M.S.",{"type":87,"investigatorFullName":88,"investigatorTitle":89,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"SPONSOR_INVESTIGATOR","Mark Niciu","Assistant Professor","100399417","university-of-iowa-interventional-psychiatry-service-patient-registry-100399417",false,"NCT04480918","University of Iowa Interventional Psychiatry Service Patient Registry","INCLUSION CRITERIA:\n\n1. 18-99 years of age\n2. English-speaker with a level of understanding sufficient to agree to clinical treatment with a treatment modality offered by the Interventional Psychiatry Service, all required research procedures, and sign an informed consent document\n3. Clinical diagnosis of a major depressive episode in the context of major depressive disorder or bipolar disorder or treatment-resistant OCD evaluated by a provider on the Interventional Psychiatry Service and felt to be an appropriate candidate for clinical treatment with a treatment modality offered by the Interventional Psychiatry Service.\n\nEXCLUSION CRITERIA:\n\n1. Age less than 18 years\n2. A primary neuropsychiatric diagnosis that is not either major depressive disorder or bipolar disorder\n3. Serious, unstable medical conditions\u002Fproblems including hepatic, renal, gastroenterologic, respiratory, cardiovascular, endocrinologic, neurologic, immunologic, or hematologic disease, e.g. uncontrolled asthma, uncontrolled hyper\u002Fhypothyroidism or active cancer.\n4. Involuntary commitment to psychiatry inpatient units\n5. If patients have one or more of the following MRI Exclusion criteria, they will not be able to participate in those aspects of this study:\n\n   1. The presence of an implanted device including pacemaker, coronary stent, defibrillator, or neurostimulation device that is not MRI-compatible\n   2. The presence of ferromagnetic objects in the body, i.e. bullets, shrapnel, and\u002For metal slivers\n   3. Clinically-significant claustrophobia\n   4. Clinically-significant hearing loss\n   5. Pregnant or nursing women or women of child bearing potential not using at least one medically accepted means of contraception (to include oral, injectable, or implant birth control, condom or diaphragm with spermicide, intrauterine devices (IUD), tubal ligation, abstinence, or partner with vasectomy)\n   6. The presence of any medical illness likely to alter brain morphology and\u002For physiology (e.g., hypertension, diabetes) even if controlled by medications","ALL","18 Years","99 Years",{"count":100,"type":101},1000,"ESTIMATED","2 Months","OBSERVATIONAL","The purpose of this study is to examine the effects of interventional\u002Fprocedural therapies for treatment-resistant depression (TRD) and Obsessive-Compulsive Disorder (OCD). These treatments include electroconvulsive therapy (ECT), transcranial magnetic stimulation (TMS), racemic ketamine infusion and intranasal esketamine insufflation. The investigators will obtain various indicators, or biomarkers, of a depressed individuals' state before, during, and\u002For after these treatments. Such biomarkers include neurobehavioral testing, neuroimaging, electroencephalography, cognitive testing, vocal recordings, epi\u002Fgenetic testing, and autonomic nervous system measures (i.e. \"fight-or-flight\" response). The results obtained from this study may provide novel antidepressant treatment response biomarkers, with the future goal of targeting a given treatment to an individual patient (\"personalized medicine\").",[106,9,107,108,109,110,111],"Treatment Resistant Depression","Major Depression","Major Depressive Disorder","Bipolar Disorder","Bipolar Depression","Obsessive-Compulsive Disorder",[113,114,30,34],"Electroconvulsive Therapy","Transcranial Magnetic Stimulation","2026-02-27",{"date":117,"type":118},"2026-03-03","ACTUAL",{"date":120,"type":118},"2020-11-02",{"date":122,"type":101},"2050-08",{"name":88,"class":6},1]